Clinical Trial Update: A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) [Phase 1]

View source ↗

Summary

Phase 1 study of AJ1-11095 in patients with primary myelofibrosis and post-polycythemia vera or post-essential thrombocythemia myelofibrosis who failed a Type I…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• AJ1-11095

Snippet

Sponsor: Ajax Therapeutics, Inc. | Conditions: Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis | Phase 1 | Status: RECRUITING